Relora supplement launch
This article was originally published in The Tan Sheet
Next Pharmaceuticals in discussions with Pharmavite, Natrol, PureTec for potential distribution of Relora-containing supplements in mass market channels, and with Nutraceutical Corp. for health food store sales. Products expected to be in all distribution channels in 30-60 days, ingredient supplier says. Relora contains proprietary plant extract from Magnolia officinalis and Phellodendron amurense and is manufactured by RJ Reynolds' Avoca division (1"The Tan Sheet" March 20, 2000, In Brief). Next is positioning the ingredient as a kava alternative, says it is "clinically shown to significantly alter the hormone levels associated with stress-induced obesity"...
You may also be interested in...
RJ Reynolds Tobacco Company's Avoca division and Next Pharmaceuticals have partnered to develop proprietary dietary supplement ingredients, the firms announce March 8. Flagship Nextracts include the COX-2 anti-inflammatory Nexprofen and Relora, a phenolic complex for anxiety and stress. Others are Standardized Echinacea Purpurea Nextract with 4% phenolic compounds and four Standardized Saw Palmetto Nextracts containing 10%, 25%, 30% and 40% total fatty acids, respectively. The January agreement follows 18 months of R&D; the agricultural and extraction facilities are located at Avoca's 2,400-acre North Carolina facility. Next is courting large pharmaceutical and supplement companies as part of the ingredients' "roll-out" phase
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.